28.17
+0.6(+2.18%)
Currency In USD
| Previous Close | 27.57 |
| Open | 27.98 |
| Day High | 28.6 |
| Day Low | 27.14 |
| 52-Week High | 41.94 |
| 52-Week Low | 16.1 |
| Volume | 1.92M |
| Average Volume | 2.3M |
| Market Cap | 3.56B |
| PE | -15.39 |
| EPS | -1.83 |
| Moving Average 50 Days | 22.17 |
| Moving Average 200 Days | 24.49 |
| Change | 0.6 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $2,007.84 as of September 03, 2025 at a share price of $28.17. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $939 as of September 03, 2025 at a share price of $28.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 11:00 AM GMT
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Date/
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
GlobeNewswire Inc.
Jul 28, 2025 11:19 PM GMT
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transpl
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 24, 2025 11:00 AM GMT
WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025,